Recent Advances in the Diagnosis and Management of High-Risk Cutaneous Squamous Cell Carcinoma.

adjuvant cutaneous squamous cell carcinoma diagnosis high-risk metastasis recurrence treatment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Jul 2022
Historique:
received: 29 06 2022
revised: 18 07 2022
accepted: 20 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

High-risk cSCC is defined as invasive cSCC staged as N0 (without detectable regional lymph nodes) and M0 (without distant metastasis), that has features associated with a higher risk of poorer prognosis. The focus of this review is on the recent advances in the diagnosis and management of high-risk cSCC. The interest in high-risk cSCC relies on its higher risk of progression to advanced cSCC, as it represents the main pool of cSCCs that give rise to advanced tumors. Assessment of the risk is thus particularly relevant for common cSCC to identify the few with a high-risk risk of local recurrence, metastasis, or disease-specific death among all other low-risk tumors. The timely diagnosis and effective treatment of high-risk cSCCs may halt their further progression and aim to prevent and lower the incidence of advanced cSCCs. Clearance of the tumor with negative surgical margins is the main goal of surgery, which is the primary treatment of cSCC. It seems that it is difficult to discern the group of high-risk cSCCs that may benefit from adjuvant RT, as a universal beneficial effect for a cSCC with any high-risk factor which was resected with clear surgical margins has not been established. In the case of a high-risk cSCC with positive margins after surgery, and re-excision not feasible, post-operative radiotherapy is performed when possible. Recommendations on further management are discussed. Regarding the follow-up of patients diagnosed with high-risk cSCC, factors to consider regarding the frequency and intensity of the follow-up schedule include the risk and possible time of occurrence of metastasis from cSCC.

Identifiants

pubmed: 35884616
pii: cancers14143556
doi: 10.3390/cancers14143556
pmc: PMC9323313
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 1:11-18
pubmed: 34855249
J Natl Compr Canc Netw. 2021 Dec;19(12):1382-1394
pubmed: 34902824
Eur J Cancer. 2020 Mar;128:60-82
pubmed: 32113941
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
J Eur Acad Dermatol Venereol. 2020 May;34(5):1080-1091
pubmed: 31587379
JAMA Dermatol. 2016 Apr;152(4):419-28
pubmed: 26762219
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1777-1787
pubmed: 33930213
J Am Acad Dermatol. 2020 Apr;82(4):920-926
pubmed: 31689446
Eur J Cancer. 2020 Mar;128:83-102
pubmed: 32113942
Am J Clin Pathol. 1990 Nov;94(5):624-7
pubmed: 2239827
Dermatology. 2022 May 12;:1-10
pubmed: 35550380
J Eur Acad Dermatol Venereol. 2007 May;21(5):591-5
pubmed: 17447971
J Am Acad Dermatol. 1992 Jun;26(6):976-90
pubmed: 1607418
J Am Acad Dermatol. 2022 Feb;86(2):331-338
pubmed: 34653569
J Am Acad Dermatol. 2020 Feb;82(2):420-429
pubmed: 31349042
Oral Oncol. 2018 Mar;78:102-107
pubmed: 29496036
Cureus. 2017 Oct 19;9(10):e1784
pubmed: 29279810
JAMA Dermatol. 2014 Jan;150(1):19-24
pubmed: 24226651
JAMA Dermatol. 2019 Oct 1;155(10):1193-1195
pubmed: 31433451
J Am Acad Dermatol. 2021 Sep;85(3):588-595
pubmed: 33524409
JAMA Dermatol. 2019 Jul 1;155(7):819-825
pubmed: 30969315
J Dtsch Dermatol Ges. 2015 Sep;13(9):942-51
pubmed: 26882393
Br J Dermatol. 2021 Mar;184(3):401-414
pubmed: 33150585
Otolaryngol Head Neck Surg. 2014 Feb;150(2):180-7
pubmed: 24201060
JAMA Otolaryngol Head Neck Surg. 2020 Feb 1;146(2):128-135
pubmed: 31804658
JAMA Dermatol. 2019 Mar 1;155(3):298-306
pubmed: 30484823
Cancer. 1985 Sep 1;56(5):1099-105
pubmed: 4016700
Am J Clin Dermatol. 2016 Oct;17(5):491-508
pubmed: 27358187
Lancet Oncol. 2008 Aug;9(8):713-20
pubmed: 18617440
J Clin Oncol. 2018 May 1;36(13):1275-1283
pubmed: 29537906
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):39-50
pubmed: 34592000
JAMA Dermatol. 2022 Feb 01;158(2):151-159
pubmed: 34964807
J Clin Oncol. 2007 May 20;25(15):1974-8
pubmed: 17513803
J Am Acad Dermatol. 2020 Jan;82(1):139-148
pubmed: 31279037
World J Surg Oncol. 2011 Jul 19;9:80
pubmed: 21771334
JAMA Dermatol. 2013 Apr;149(4):402-10
pubmed: 23325457
J Clin Oncol. 2014 Feb 1;32(4):327-34
pubmed: 24366933
J Am Acad Dermatol. 2021 Feb;84(2):361-369
pubmed: 32344066
J Am Acad Dermatol. 2022 Jun;86(6):1246-1257
pubmed: 34890701
Ann Plast Surg. 2015 Sep;75(3):323-6
pubmed: 24401812
J Invest Dermatol. 2017 Nov;137(11):2309-2315
pubmed: 28736229
Dermatol Surg. 2021 May 1;47(5):587-592
pubmed: 33577212
J Am Acad Dermatol. 2021 Jun;84(6):1708-1712
pubmed: 32781186
J Clin Oncol. 2005 Feb 1;23(4):759-65
pubmed: 15681519
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
J Am Acad Dermatol. 2022 Jul;87(1):64-71
pubmed: 35259451
J Am Acad Dermatol. 2022 Jul;87(1):87-94
pubmed: 35364211
J Am Acad Dermatol. 2017 Feb;76(2):217-225
pubmed: 27707594
Future Oncol. 2022 Mar;18(7):833-847
pubmed: 34821148
J Dtsch Dermatol Ges. 2006 Dec;4(12):1080-4
pubmed: 17176417
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1275-81
pubmed: 23182701
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):846-854
pubmed: 35224776
J Am Acad Dermatol. 2015 Jul;73(1):127-37
pubmed: 26089049
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
BMJ. 2013 Nov 04;347:f6153
pubmed: 24191270
Eur J Cancer. 2010 Jun;46(9):1563-72
pubmed: 20338745
Br J Plast Surg. 2002 Jun;55(4):287-92
pubmed: 12160533

Auteurs

Clio Dessinioti (C)

1st Department of Dermatology, Skin Cancer and Melanoma Unit, Andreas Sygros Hospital, University of Athens, 16121 Athens, Greece.

Alexander J Stratigos (AJ)

1st Department of Dermatology, Skin Cancer and Melanoma Unit, Andreas Sygros Hospital, University of Athens, 16121 Athens, Greece.

Classifications MeSH